To date, studies remain divided as to whether including apolipoproteins in risk models improves classification. Supporting their inclusion, ApoB and the ratio of ApoB to apolipoprotein A-I (ApoA-I) have been shown to associate with adverse cardiovascular outcomes and have been suggested to predict events more accurately than routine cholesterol measures, such as low-density lipoprotein-cholesterol (LDL-C), the ratio of total cholesterol (TC)/high density lipoprotein-cholesterol (HDL-C), or non-HDL-C (ie, TC-HDL-C) in case-control, [2] [3] [4] prospective, [5] [6] [7] [8] [9] and interventional studies. [10] [11] [12] In contrast, null findings have also been reported-prospective studies including the Women's Health study, 13 Framingham Offspring Study, 14 European Prospective Investigation into Cancer and Nutrition, 15 and the Atherosclerosis Risk in Communities study 16, 17 showed that ApoB provides no additional risk information beyond the current lipid panel. Similar to ApoB, total LDL particle (LDL-P) concentrations derived from nuclear magnetic resonance (NMR) spectroscopy have also been shown to associate with risk of cardiovascular disease (CVD) and coronary heart disease (CHD) [18] [19] [20] but may be equivalent to standard lipid measures in predicting future events. 18, 20 Overall, evidence to support the clinical use of NMR or apolipoprotein measurements is equivocal, yet there may be a benefit of incorporating lipoprotein particle concentrations to risk profiles for a more complete assessment of lipoprotein phenotype, and by extension, disease risk.
In the present analysis of 4679 Multi-Ethnic Study of Atherosclerosis (MESA) participants for an 8.5-year followup period, we first compared the standard lipid panel with nonstandard measurements ApoB and the ratio of ApoB/ ApoA-I as well as NMR spectroscopy-derived measures of total LDL-P and the ratio of LDL-P to HDL-particles (HDL-P) for evaluating CHD risk. We then determined whether these lipoprotein measures may impart risk independent of cholesterol measures. Finally, we used the AHA/ACC risk calculator score as a baseline prediction model and determined whether individual additions of ApoB, ApoB/ApoA-I, LDL-P, or LDL-P/HDL-P improved CHD risk prediction.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Unadjusted demographic, clinical, and lifestyle characteristics of 4679 MESA participants are shown in Table 1 .
Estimated hazard ratios (HRs) for CHD outcomes by quartiles of LDL-C, non-HDL-C, TC/HDL-C, ApoB, ApoB/ ApoA-I, total LDL-P, and LDL-P/HDL-P are presented in Table 2 . Adjustments were made for nonlipid measures, including sex, systolic blood pressure, hypertension medication use, age, and race/ethnicity. Lipid-lowering medication that began after baseline did not alter results significantly and was not included in the model. All lipid and apolipoprotein measures were found to be significantly associated with risk of incident CHD. Individuals with lipid or apolipoprotein levels in the fourth quartiles were found to be at significantly greater risk of incident CHD than those in the first quartile: LDL-C (HR, 1.62; confidence interval [CI], 1.11-2.35), non-HDL-C (HR, 1.99; 95% CI, 1.36-2.90), TC/HDL-C (HR, 2.24; 95% CI, 1.50-3.33), ApoB (HR, 1.84; 95% CI, 1.25-2.69), ApoB/ ApoA-I (HR, 1.91; 95% CI, 1.32-2.76), total LDL-particles (HR, 1.77; 95% CI, 1.21-2.58), and LDL-P/HDL-P (HR, 2.28; 95% CI, 1.54-3.37). Given the presence of 4 ethnicities/ races in this subcohort, an interaction analysis was performed (Tables I and II in the ApoA-I, LDL-P, and LDL-P/HDL-P would associate with CHD event outcomes independent of LDL-C, non-HDL-C, TC/HDL-C, or all lipid panel variables TC, LDL-C, HDL-C, and triglycerides (Table 3 ). Cox proportional hazards analyses were conducted, and adjustments were made for sex, hypertension medication, systolic blood pressure, age, diabetes mellitus, smoking, and race/ethnicity, with individual adjustments for LDL-C, non-HDL-C, or TC/HDL-C, followed by a combination of TC, LDL-C, HDL-C, and triglycerides. After adjustment for LDL-C, significant associations with incident CHD were observed for individuals in the fourth quartiles for ApoB (HR, 1.99; 95% CI, 1.18-3.36), ApoB/ ApoA-I (HR, 1.86; 95% CI, 1.21-2.85), total LDL-P (HR, 1.75; 95% CI, 1.11-2.75), and LDL-P/HDL-P (HR, 2.303; 95% CI, 1.49-3.57). After adjustment for non-HDL-C, associations with future incident CHD were observed for the top quartiles of ApoB (HR, 1.83; 95% CI, 1.01-3.34), ApoB/ ApoA-I (HR, 1.72; 95% CI, 1.10-2.70), and LDL-P/HDL-P (HR, 2.25; 95% CI, 1.43-3.55). No significant associations were found between total LDL-P and CHD after adjustment for non-HDL-C. Only the association of LDL-P/HDL-P with CHD was observed for individuals in the fourth quartiles after adjustment for TC/HDL-C (HR, 2.02; 95% CI, 1.19, 3.42). Finally, on adjusting for all variables in the standard lipid panel (TC, LDL-C, HDL-C, and triglycerides), no significant associations were observed with CHD.
Table 2. Risk of Incident CHD Are Expressed as Hazard Ratios Followed by 95% Confidence Intervals and P Values for LDL-C, Non-HDL-C, TC/HDL-C, ApoB, ApoB/ApoA-I, Total LDL-P Concentration (Nuclear Magnetic Resonance Spectroscopy) or the Ratio of LDL-P to HDL-P in 4679 Multi-Ethnic Study of Atherosclerosis Participants Adjusted for Nonlipid Variables* CHD 233 Events
Qrt LDL-C Non-HDL-C TC/HDL-C ApoB ApoB/ApoA LDL-P LDL-P/HDL-P ApoA-I indicates apolipoprotein A-I; ApoB, apolipoproteins B-100; CHD, coronary heart disease; HDL-C, high-density lipoproteincholesterol; HDL-P, HDL particle; LDL-C, low-density lipoprotein-cholesterol; LDL-P, LDL particle; and TC, total cholesterol. *Adjusted for nonlipid risk factors, including sex, hypertension meds, systolic blood pressure, age (category), diabetes mellitus, smoking, and race/ethnicity. †Results for each marker are presented as hazard ratios for individuals in fourth quartiles, using respective first quartiles as referents; 95% confidence intervals and P values are specified.
Net reclassification improvement (NRI) and c-statistics were used to evaluate the performance of each lipid or lipoprotein marker when added to a baseline 2013 AHA/ACC cardiovascular risk calculator score. The total NRI represents the combination of reclassifications for CHD cases or events (M event ) and nonevents (M nonevent ). M event is the proportion of event subjects whose calculated probability of having an event in the new model is greater than that in the baseline model; a positive M event represents an improvement in sensitivity of the new model. In contrast, M nonevent is the proportion of nonevent subjects whose predicted probability of having an event in the new model is greater than that in the baseline model; a negative M nonevent represents an improvement in model specificity, whereas a positive M nonevent represents a greater number of false-positives and decrease in specificity. All NRI reclassifications, ie, total, events (M event ), and nonevents (M nonevent ), are reported in Table 4 . TC/HDL-C, LDL-P/HDL-P, and ApoB/ApoA-I ratios were found to improve the AHA/ACC risk score for incident CHD significantly. ApoB/ApoA-I improved reclassification of events (M event =0.43) but incorrectly reclassified nonevents (M nonevent =0.24), resulting in a total NRI of 0.18 (P=0.007). LDL-P/HDL-P improved reclassification of events (M event =0.39) but incorrectly reclassified nonevents (M nonevent =0.25), resulting in a total NRI of 0.145 (P<0.001). Likewise, TC/HDL-C improved reclassification of events (M event =0.58) but incorrectly reclassified nonevents (M nonevent =0.46), resulting in a total NRI of 0.12 (P=0.03).
In contrast to NRI scores, c-statistics revealed no significant improvements with the addition of any lipid or lipoprotein to the AHA/ACC baseline model. Respective c-statistics for the baseline AHA/ACC model and with the addition of each lipid/lipoprotein were as follows: AHA/ACC=0. 730, LDL-C=0. 727, non-HDL-C=0. 724, TC/HDL-C ratio=0.726, LDL-P=0.725, LDL-P/HDL-P=0.727, ApoB=0.728, and ApoB/ApoA-I ratio=0.736.
Discussion
A 2013 report from the AHA/ACC task force on risk assessment states that there is insufficient evidence to include ApoB or ApoB/ApoA-I to current risk guidelines. 1 We found that elevated levels of ApoB, ApoB/ApoA-I, as well as NMR-derived total LDL-P and LDL-P/HDL-P, were significantly associated with future CHD events although only the association of LDL-P/HDL-P remained significant after adjustment for TC/HDL-C. Upon adjusting for traditional lipid panel variables of TC, LDL-C, HDL-C, and triglycerides, no associations remained significant. NRI analysis revealed that including TC/HDL-C, ApoB/ApoA-I, or LDL-P/HDL-P to the 2013 AHA/ACC risk score significantly reclassified individuals by improving sensitivity; however, the improvement of sensitivity comes at the expense of decreased specificity in all cases. C-statistics revealed that neither apolipoproteins nor NMR measures significantly improved event prediction.
Previous studies have reported inconsistent findings as to whether apolipoproteins identify disease risk more effectively than traditional lipid measures. Results from 2 of the largest studies to date, Apolipoprotein MOrtality RISk study (AMORIS, n=175,553) and INTERHEART (n=9345 acute MI cases, n=12 120 controls) indicate that respective measures of ApoB/ApoA-I and ApoB may improve CHD risk assessment. 2, 5 Conducted across 52 countries in 12 461 cases and 14 637 controls, the INTERHEART study showed that the ratio of ApoB/ApoA-I was significantly associated with MI risk (odds ratio, 1.59)-greater than either non-HDL-C (odds ratio, 1.21) or TC/HDL-C (odds ratio, 1.17). 2 In the prospective AMORIS study, investigators found that ApoB was more accurate in predicting fatal MI than LDL-C over an ≈5.5-year follow-up. 5 In agreement with AMORIS and INTERHEART, a host of additional studies, 3, 4, [6] [7] [8] including the National Health and Nutrition Examination Survey 9 as well as clinical trials for statin therapies, Air Force Coronary/Texas Atherosclerosis Prevention Study 11 and Long-term Intervention with Pravastatin in Ischemic Disease, 12 have indicated that apolipoprotein measurement may either be a useful addition to or replacement of standard lipid measures in evaluating disease risk. Particularly noteworthy, the Air Force Coronary/Texas Atherosclerosis Prevention Study showed that ApoB, but not LDL-C, predicted primary coronary events at baseline and on statin therapy-demonstrating that it may have value over LDL-C measurement. 11 A recent and comprehensive meta-analysis of 12 epidemiological studies (n=233 455; events=22 950) conducted by Sniderman et al 21 confirmed the above study findings. The authors concluded that ApoB (relative risk, 1.43; 95% CI, 1.35-1.51) is superior to non-HDL-C (relative risk, 1.34; 95% CI, 1.24-1.44) and LDL-C (relative risk, 1.25; 95% CI, 1.18-1.33) in associating with future fatal or nonfatal ischemic cardiovascular events. Total net reclassification improvement with P values and subcategories of reclassified events and nonevents are shown. ApoA-I indicates apolipoprotein A-I; ApoB, apolipoproteins B-100; CHD, coronary heart disease; HDL-C, high-density lipoprotein-cholesterol; HDL-P, HDL particle; LDL-C, low-density lipoprotein cholesterol; LDL-P, LDL particle; NRI, net reclassification improvement; and TC, total cholesterol. *Significance, P ≤0.05. February 2015
Table 4. Net Reclassification Improvement of Predicted Risk for Myocardial Infarction, Resuscitated Cardiac Arrest, or CHD Death >8.5 Years With the Singular Addition of the Specified Lipid or Lipoprotein Measure to a Baseline Model of the 2013 American Heart Association/American College of Cardiology Risk Calculator
Contrary to the above evidence, other studies have demonstrated that ApoB and ApoB/ApoA-I do not improve risk assessment over the standard lipid panel. An early prospective study conducted during a 10-year follow-up period in Atherosclerosis Risk in Communities participants was one of the first to show that ApoB and ApoA-I are not associated with higher CHD risk in models that accounted for LDL-C, HDL-C, and triglyceride levels. 16 Subsequent studies have since compared ApoB with non-HDL-C. Framingham Offspring (15-year follow-up), 14 European Prospective Investigation into Cancer and Nutrition (11.4-year followup), 15 and the Women's Health Study (11- year follow-up) 13 found that ApoB and non-HDL-C were equivalent in their associations with CHD risk. This last prospective study by Mora et al 13 further reported that the ApoB/ApoA-I ratio conferred a 2.79-fold higher risk for incident CVD, similar to that of the TC/HDL-C ratio, HR=2.82. Calculation of NRI for apolipoprotein measures demonstrated limited improvement in CVD risk assessment compared with the TC/HDL-C ratio (<2%). Finally, a 2009 meta-analysis composed of 22 studies (n=91 307; events=4449) reported that the ratio of ApoB to ApoA-I showed a similar association with future CHD as non-HDL-C/HDL-C. 22 Our findings largely agree with these latter studies that ApoB, ApoB/ ApoA-I, and standard lipid measures are comparably associated with future CHD outcomes.
The core reasons for the disparities among studies remain unclear, but differences in study populations, statistical models and covariates, assay methodologies, CHD end points, length of study follow-up periods, or a combination of these and other factors may be involved. In the Women's Health Study cohort, Mora et al 13 suggested that fully adjusted models with lifestyle and demographic information may result in study differences. This observation is particularly relevant because sex, 16 age, 6 and the presence of diabetes mellitus 23 may influence the association of ApoB with CVD risk although an effect of age has also been refuted. 21 These differences may contribute to the incongruent associations with CVD/CHD incidence and should be considered when evaluating the clinical use of apolipoproteins. A final possibility remains that the value in apolipoprotein measurements relies on identifying individuals with uncommon lipid profiles where cholesterol is normal but lipoprotein particle numbers are high-a so-called discordant phenotype. 24 Most studies, including MESA, do not have an adequate number of CHD outcomes to test this hypothesis.
NMR-Derived Total LDL Particle Number
NMR has also been proposed as a more accurate means of identifying CHD risk by quantifying the sizes and total concentrations of lipoproteins, including LDL and HDL. Although NMR measures are not as well-studied as apolipoproteins, it is generally accepted that elevated LDL-P concentrations convey risk of CVD or CHD. 13, 18, 24, 25 It has been reported further that LDL-P is superior to LDL-C in assessing disease risk, 13, 18, 19 but more recent studies suggest that LDL-P is equivalent to LDL-C and non-HDL-C. 13, 24, 25 Our findings agree with the latter studies that total LDL-P is similar to non-HDL-C because a relationship was not observed after its adjustment.
In contrast, the ratio of LDL-P/HDL-P was found to associate with CHD independent of LDL-C, non-HDL-C, or TC/HDL-C. To date, we demonstrate that it conveys risk of CHD independent of these cholesterol measures; however, few studies have examined LDL-P/HDL-P in relation to CHD events. 26 Given the paucity of data, the significance of this result remains highly uncertain until additional studies either confirm or refute our finding in this regard.
CHD Risk Classification
The 2013 AHA/ACC risk calculator score served as the baseline model, and improvement in event prediction was tested with the addition of each lipid and lipoprotein variable. NRI analysis revealed that adding ApoB/ApoA-I, LDL-P/HDL-P, or TC/HDL-C ratios modestly improved the prediction of future CHD events (myocardial infarction, resuscitated cardiac arrest, or CHD death); however, interpreting these results is not straightforward. For instance, the addition of ApoB/ApoA-I identified 42.8% of the population who had a CHD event (or 60 individuals) as being at higher risk when compared with the baseline model. However, this increased sensitivity comes at the expense of specificity-adding ApoB/ApoA-I to the baseline model predicted higher CHD risk for 24.5% of those who did not have events (or 1102 individuals). Supplementing these findings, the c-statistic revealed no improvement in event prediction with the addition of any measure to the AHA/ ACC baseline model although this finding was expected because it is a more conservative test than NRI. Taken together, the addition of ApoB/ApoA-I or LDL-P/HDL-P may modestly improve sensitivity for detecting CHD risk but reduces specificity-potentially explaining the null findings for their respective c-statistics. Additional studies are warranted to determine whether the higher sensitivity but lower specificity offered by NMR or apolipoprotein testing is cost effective.
Strengths and Limitations
The present analysis contains several limitations. First, it must be acknowledged that the AHA/ACC guidelines were developed using CHD and ischemic stroke as outcome variables. Our analysis restricted outcomes to CHD alone using a broader definition to include instances of angina when followed by coronary artery bypass and where obstruction was found to be ≥70%. In addition, there may be a selection bias in the present study because individuals taking lipidlowering medication at baseline were excluded, potentially skewing results toward the null finding. In our statistical model, we adjusted for multiple variables; however, we cannot discount the presence of residual confounding. Apart from potential confounding, we recognize the importance of subanalyses by sex, race, and other subgroups, but did not have the statistical power to stratify the population. Although our analysis was limited by the relatively few CHD events, statistically significant findings were still apparent.
Conclusions
The present analysis represents a comprehensive evaluation of lipoprotein and apolipoprotein measurements and their associations with future CHD events. The association of LDL-P/HDL-P ratio with CHD independent of individual standard lipid measures may be a novel finding but requires confirmation by other large prospective studies. In comparison, our findings for ApoB/ApoA-I were largely equivocal. Although ApoB/ApoA-I increased sensitivity, the lower specificity, and c-statistic results do not support its measurement. Moreover, the attenuated associations after adjustment for lipid variables indicate that lipoprotein particle measures do not detect risk that is unaccounted for by the standard lipid panel. Lipoprotein measurement may yet be useful in identifying risk in a subgroup of individuals, but a larger population of those with a discordant lipid-lipoprotein phenotype is necessary to determine whether such testing is cost effective.
